Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01565590 · ClinicalTrials.gov registry record · Phase 3

Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage

A Phase 3 study, sponsored by University of Cincinnati.

Terminated
Registry status
Phase 3
Development phase
4
Enrollment target

NCT01565590 is a Phase 3 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01565590, a Phase 3 study, was terminated before completion, sponsored by University of Cincinnati.

TERMINATED
Registry status
Phase 3
Development phase
4 participants
Enrollment target

Study Summary

The purpose of this research is to compare patients with aneurysmal subarachnoid hemorrhage on dexmedetomidine compared to propofol to assess if one group has decreased inflammation. The investigators hypothesis is that the group assigned to receive dexmedetomidine will have a more profound decrease in markers of inflammation over time.

Interventions

  • DRUG Dexmedetomidine
  • DRUG propofol

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2012-02
Est. Completion 2015-07
Phase Phase 3

Sponsor

University of Cincinnati

245 total trials

What the Registry Record Tells You About NCT01565590

The ClinicalTrials.gov registry entry for NCT01565590 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dexmedetomidine is the first listed.

NCT01565590 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01565590 about?

NCT01565590 is a clinical study titled "Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage". The purpose of this research is to compare patients with aneurysmal subarachnoid hemorrhage on dexmedetomidine compared to propofol to assess if one group has decreased inflammation. The investigators hypothesis is that the group assigned to receive dexmedetomidine will have a more profound decrease...

What is the current status of trial NCT01565590?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2012-02. Estimated completion is 2015-07.

What interventions are being tested in trial NCT01565590?

The interventions under investigation include: Dexmedetomidine (DRUG), propofol (DRUG).

Who is sponsoring clinical trial NCT01565590?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.